ABT Debt / Equity | ABBOTT LABORATORIES

ABBOTT LABORATORIES (ABT) Debt / Equity

2026-03-31: Debt/Equity Ratio 0.65.
2025-12-31: Debt/Equity Ratio 0.25.
2025-09-30: Debt/Equity Ratio 0.25.
2025-06-30: Debt/Equity Ratio 0.27.

Complete source-backed debt/equity ratio history.

Available history: 2007-12-31 to 2026-03-31
Data captured: 2026-09-04

Historical Debt/Equity Ratio

Date	Debt/Equity Ratio
2026-03-31	0.65
2025-12-31	0.25
2025-09-30	0.25
2025-06-30	0.27
2025-03-31	0.27
2024-12-31	0.3
2024-09-30	0.38
2024-06-30	0.38
2024-03-31	0.38
2023-12-31	0.38
2023-09-30	0.41
2023-06-30	0.45
2023-03-31	0.46
2022-12-31	0.46
2022-09-30	0.46
2022-06-30	0.46
2022-03-31	0.48
2021-12-31	0.5
2021-09-30	0.53
2021-06-30	0.54
2021-03-31	0.54
2020-12-31	0.57
2020-09-30	0.58
2020-06-30	0.64
2020-03-31	0.6
2019-12-31	0.58
2019-09-30	0.59
2019-06-30	0.6
2019-03-31	0.61
2018-12-31	0.63
2018-09-30	0.76
2018-06-30	0.66
2018-03-31	0.69
2017-12-31	0.9
2017-09-30	0.74
2017-06-30	0.75
2017-03-31	0.76
2016-12-31	1.01
2016-09-30	0.29
2016-06-30	0.29
2016-03-31	0.29
2015-12-31	0.28
2015-09-30	0.28
2015-06-30	0.26
2015-03-31	0.27
2014-12-31	0.16
2014-09-30	0.17
2014-06-30	0.14
2014-03-31	0.15
2013-12-31	0.13
2013-09-30	0.15
2013-06-30	0.16
2013-03-31	0.17
2012-12-31	0.69
2012-09-30	0.48
2012-06-30	0.53
2012-03-31	0.51
2011-12-31	0.53
2011-09-30	0.53
2011-06-30	0.48
2011-03-31	0.57
2010-12-31	0.64
2010-09-30	0.71
2010-06-30	0.74
2010-03-31	0.56
2009-12-31	0.5
2009-09-30	0.54
2009-06-30	0.57
2008-12-31	0.56
2007-12-31	0.58

Annual Debt/Equity Ratio

Date	Debt/Equity Ratio
2025-12-31	0.25
2024-12-31	0.3
2023-12-31	0.38
2022-12-31	0.46
2021-12-31	0.5
2020-12-31	0.57
2019-12-31	0.58
2018-12-31	0.63
2017-12-31	0.9
2016-12-31	1.01
2015-12-31	0.28
2014-12-31	0.16
2013-12-31	0.13
2012-12-31	0.69
2011-12-31	0.53
2010-12-31	0.64
2009-12-31	0.5
2008-12-31	0.56
2007-12-31	0.58

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
PFIZER INC (PFE)	United States	$162.042B	31.94
VERTEX PHARMACEUTICALS INC / MA (VRTX)	United States	$132.481B	28.56
BRISTOL MYERS SQUIBB CO (BMY)	United States	$125.637B	12.67
REGENERON PHARMACEUTICALS, INC. (REGN)	United States	$74.751B	21.53
ALNYLAM PHARMACEUTICALS, INC. (ALNY)	United States	$33.420B	54.94
Zoetis Inc. (ZTS)	United States	$29.045B	11.38
INSMED Inc (INSM)	United States	$26.566B	-26.60
Roivant Sciences Ltd. (ROIV)		$26.105B	-96.08
Royalty Pharma plc (RPRX)	United States	$22.628B
UNITED THERAPEUTICS Corp (UTHR)	United States	$20.249B	17.64